Works matching IS 25094254 AND DT 2024 AND VI 8 AND IP 3

Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany.

Published in:

PharmacoEconomics - Open, 2024, v. 8, n. 3, p. 373, doi. 10.1007/s41669-024-00480-z

By:

• Meier, Niklaus;
• Fuchs, Hendrik;
• Galactionova, Katya;
• Hermans, Cedric;
• Pletscher, Mark;
• Schwenkglenks, Matthias

Publication type:

Article